カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界のベクター化抗体市場予測2023-2029：アデノ随伴ウイルス（AAV）ベクター、エレクトロポレーション、脂質ナノ粒子（LNP）、その他

【英語タイトル】Vectorized Antibodies Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8199）・商品コード：MMG23LY8199
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：77
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医療機器＆消耗品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のベクター化抗体市場規模と予測を収録しています。・世界のベクター化抗体市場：売上、2018年-2023年、2024年-2029年
・世界のベクター化抗体市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のベクター化抗体市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アデノ随伴ウイルス（AAV）ベクター」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

ベクター化抗体のグローバル主要企業は、4D Molecular Therapeutics (4DMT)、 AbbVie、 Adverum Biotechnologies、 AstraZeneca、 BioNTech、 Curevac、 Eli Lilly、 Generation Bio、 Genmab、 GlaxoSmithKline、 Homology Medicines、 Inovio Pharmaceuticals、 Kernal Biologics、 VectorYなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、ベクター化抗体のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のベクター化抗体市場：タイプ別、2018年-2023年、2024年-2029年
世界のベクター化抗体市場：タイプ別市場シェア、2022年
・アデノ随伴ウイルス（AAV）ベクター、エレクトロポレーション、脂質ナノ粒子（LNP）、その他

世界のベクター化抗体市場：用途別、2018年-2023年、2024年-2029年
世界のベクター化抗体市場：用途別市場シェア、2022年
・病院、専門クリニック、バイオテクノロジー企業、HIV-AIDS治療センター、その他

世界のベクター化抗体市場：地域・国別、2018年-2023年、2024年-2029年
世界のベクター化抗体市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるベクター化抗体のグローバル売上、2018年-2023年
・主要企業におけるベクター化抗体のグローバル売上シェア、2022年
・主要企業におけるベクター化抗体のグローバル販売量、2018年-2023年
・主要企業におけるベクター化抗体のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
4D Molecular Therapeutics (4DMT)、 AbbVie、 Adverum Biotechnologies、 AstraZeneca、 BioNTech、 Curevac、 Eli Lilly、 Generation Bio、 Genmab、 GlaxoSmithKline、 Homology Medicines、 Inovio Pharmaceuticals、 Kernal Biologics、 VectorY

*************************************************************

・調査・分析レポートの概要
ベクター化抗体市場の定義
市場セグメント
世界のベクター化抗体市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のベクター化抗体市場規模
世界のベクター化抗体市場規模：2022年 VS 2029年
世界のベクター化抗体市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのベクター化抗体の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のベクター化抗体製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：アデノ随伴ウイルス（AAV）ベクター、エレクトロポレーション、脂質ナノ粒子（LNP）、その他
ベクター化抗体のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、専門クリニック、バイオテクノロジー企業、HIV-AIDS治療センター、その他
ベクター化抗体の用途別グローバル売上・予測

・地域別市場分析
地域別ベクター化抗体市場規模 2022年と2029年
地域別ベクター化抗体売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
4D Molecular Therapeutics (4DMT)、 AbbVie、 Adverum Biotechnologies、 AstraZeneca、 BioNTech、 Curevac、 Eli Lilly、 Generation Bio、 Genmab、 GlaxoSmithKline、 Homology Medicines、 Inovio Pharmaceuticals、 Kernal Biologics、 VectorY
...

Vectorized Antibodies are used as a treatment for HIV-Aids, which not only prevents transmission but also inhibit the replication of HIV infections. Vectorized Antibodies overcome the challenge of antibodies to enter the blood brain barrier.
This report aims to provide a comprehensive presentation of the global market for Vectorized Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vectorized Antibodies. This report contains market size and forecasts of Vectorized Antibodies in global, including the following market information:
Global Vectorized Antibodies Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Vectorized Antibodies Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Vectorized Antibodies companies in 2022 (%)
The global Vectorized Antibodies market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Adenoassociated Virus (AAV) Vector Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Vectorized Antibodies include 4D Molecular Therapeutics (4DMT), AbbVie, Adverum Biotechnologies, AstraZeneca, BioNTech, Curevac, Eli Lilly, Generation Bio and Genmab, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Vectorized Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vectorized Antibodies Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Vectorized Antibodies Market Segment Percentages, by Type, 2022 (%)
Adenoassociated Virus (AAV) Vector
Electroporation
Lipid Nanoparticles (LNPs)
Others
Global Vectorized Antibodies Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Vectorized Antibodies Market Segment Percentages, by Application, 2022 (%)
Hospitals
Specialized Clinics
Biotech Companies
HIV-AIDS Treatment Centers
Others
Global Vectorized Antibodies Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Vectorized Antibodies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Vectorized Antibodies revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Vectorized Antibodies revenues share in global market, 2022 (%)
Key companies Vectorized Antibodies sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Vectorized Antibodies sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
4D Molecular Therapeutics (4DMT)
AbbVie
Adverum Biotechnologies
AstraZeneca
BioNTech
Curevac
Eli Lilly
Generation Bio
Genmab
GlaxoSmithKline
Homology Medicines
Inovio Pharmaceuticals
Kernal Biologics
VectorY
Outline of Major Chapters:
Chapter 1: Introduces the definition of Vectorized Antibodies, market overview.
Chapter 2: Global Vectorized Antibodies market size in revenue and volume.
Chapter 3: Detailed analysis of Vectorized Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Vectorized Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Vectorized Antibodies capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Vectorized Antibodies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Vectorized Antibodies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Vectorized Antibodies Overall Market Size
2.1 Global Vectorized Antibodies Market Size: 2022 VS 2029
2.2 Global Vectorized Antibodies Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Vectorized Antibodies Sales: 2018-2029
3 Company Landscape
3.1 Top Vectorized Antibodies Players in Global Market
3.2 Top Global Vectorized Antibodies Companies Ranked by Revenue
3.3 Global Vectorized Antibodies Revenue by Companies
3.4 Global Vectorized Antibodies Sales by Companies
3.5 Global Vectorized Antibodies Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Vectorized Antibodies Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Vectorized Antibodies Product Type
3.8 Tier 1, Tier 2 and Tier 3 Vectorized Antibodies Players in Global Market
3.8.1 List of Global Tier 1 Vectorized Antibodies Companies
3.8.2 List of Global Tier 2 and Tier 3 Vectorized Antibodies Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Vectorized Antibodies Market Size Markets, 2022 & 2029
4.1.2 Adenoassociated Virus (AAV) Vector
4.1.3 Electroporation
4.1.4 Lipid Nanoparticles (LNPs)
4.1.5 Others
4.2 By Type – Global Vectorized Antibodies Revenue & Forecasts
4.2.1 By Type – Global Vectorized Antibodies Revenue, 2018-2023
4.2.2 By Type – Global Vectorized Antibodies Revenue, 2024-2029
4.2.3 By Type – Global Vectorized Antibodies Revenue Market Share, 2018-2029
4.3 By Type – Global Vectorized Antibodies Sales & Forecasts
4.3.1 By Type – Global Vectorized Antibodies Sales, 2018-2023
4.3.2 By Type – Global Vectorized Antibodies Sales, 2024-2029
4.3.3 By Type – Global Vectorized Antibodies Sales Market Share, 2018-2029
4.4 By Type – Global Vectorized Antibodies Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Vectorized Antibodies Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Specialized Clinics
5.1.4 Biotech Companies
5.1.5 HIV-AIDS Treatment Centers
5.1.6 Others
5.2 By Application – Global Vectorized Antibodies Revenue & Forecasts
5.2.1 By Application – Global Vectorized Antibodies Revenue, 2018-2023
5.2.2 By Application – Global Vectorized Antibodies Revenue, 2024-2029
5.2.3 By Application – Global Vectorized Antibodies Revenue Market Share, 2018-2029
5.3 By Application – Global Vectorized Antibodies Sales & Forecasts
5.3.1 By Application – Global Vectorized Antibodies Sales, 2018-2023
5.3.2 By Application – Global Vectorized Antibodies Sales, 2024-2029
5.3.3 By Application – Global Vectorized Antibodies Sales Market Share, 2018-2029
5.4 By Application – Global Vectorized Antibodies Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Vectorized Antibodies Market Size, 2022 & 2029
6.2 By Region – Global Vectorized Antibodies Revenue & Forecasts
6.2.1 By Region – Global Vectorized Antibodies Revenue, 2018-2023
6.2.2 By Region – Global Vectorized Antibodies Revenue, 2024-2029
6.2.3 By Region – Global Vectorized Antibodies Revenue Market Share, 2018-2029
6.3 By Region – Global Vectorized Antibodies Sales & Forecasts
6.3.1 By Region – Global Vectorized Antibodies Sales, 2018-2023
6.3.2 By Region – Global Vectorized Antibodies Sales, 2024-2029
6.3.3 By Region – Global Vectorized Antibodies Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Vectorized Antibodies Revenue, 2018-2029
6.4.2 By Country – North America Vectorized Antibodies Sales, 2018-2029
6.4.3 US Vectorized Antibodies Market Size, 2018-2029
6.4.4 Canada Vectorized Antibodies Market Size, 2018-2029
6.4.5 Mexico Vectorized Antibodies Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Vectorized Antibodies Revenue, 2018-2029
6.5.2 By Country – Europe Vectorized Antibodies Sales, 2018-2029
6.5.3 Germany Vectorized Antibodies Market Size, 2018-2029
6.5.4 France Vectorized Antibodies Market Size, 2018-2029
6.5.5 U.K. Vectorized Antibodies Market Size, 2018-2029
6.5.6 Italy Vectorized Antibodies Market Size, 2018-2029
6.5.7 Russia Vectorized Antibodies Market Size, 2018-2029
6.5.8 Nordic Countries Vectorized Antibodies Market Size, 2018-2029
6.5.9 Benelux Vectorized Antibodies Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Vectorized Antibodies Revenue, 2018-2029
6.6.2 By Region – Asia Vectorized Antibodies Sales, 2018-2029
6.6.3 China Vectorized Antibodies Market Size, 2018-2029
6.6.4 Japan Vectorized Antibodies Market Size, 2018-2029
6.6.5 South Korea Vectorized Antibodies Market Size, 2018-2029
6.6.6 Southeast Asia Vectorized Antibodies Market Size, 2018-2029
6.6.7 India Vectorized Antibodies Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Vectorized Antibodies Revenue, 2018-2029
6.7.2 By Country – South America Vectorized Antibodies Sales, 2018-2029
6.7.3 Brazil Vectorized Antibodies Market Size, 2018-2029
6.7.4 Argentina Vectorized Antibodies Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Vectorized Antibodies Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Vectorized Antibodies Sales, 2018-2029
6.8.3 Turkey Vectorized Antibodies Market Size, 2018-2029
6.8.4 Israel Vectorized Antibodies Market Size, 2018-2029
6.8.5 Saudi Arabia Vectorized Antibodies Market Size, 2018-2029
6.8.6 UAE Vectorized Antibodies Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 4D Molecular Therapeutics (4DMT)
7.1.1 4D Molecular Therapeutics (4DMT) Company Summary
7.1.2 4D Molecular Therapeutics (4DMT) Business Overview
7.1.3 4D Molecular Therapeutics (4DMT) Vectorized Antibodies Major Product Offerings
7.1.4 4D Molecular Therapeutics (4DMT) Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.1.5 4D Molecular Therapeutics (4DMT) Key News & Latest Developments
7.2 AbbVie
7.2.1 AbbVie Company Summary
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Vectorized Antibodies Major Product Offerings
7.2.4 AbbVie Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Key News & Latest Developments
7.3 Adverum Biotechnologies
7.3.1 Adverum Biotechnologies Company Summary
7.3.2 Adverum Biotechnologies Business Overview
7.3.3 Adverum Biotechnologies Vectorized Antibodies Major Product Offerings
7.3.4 Adverum Biotechnologies Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.3.5 Adverum Biotechnologies Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Vectorized Antibodies Major Product Offerings
7.4.4 AstraZeneca Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 BioNTech
7.5.1 BioNTech Company Summary
7.5.2 BioNTech Business Overview
7.5.3 BioNTech Vectorized Antibodies Major Product Offerings
7.5.4 BioNTech Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.5.5 BioNTech Key News & Latest Developments
7.6 Curevac
7.6.1 Curevac Company Summary
7.6.2 Curevac Business Overview
7.6.3 Curevac Vectorized Antibodies Major Product Offerings
7.6.4 Curevac Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.6.5 Curevac Key News & Latest Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Company Summary
7.7.2 Eli Lilly Business Overview
7.7.3 Eli Lilly Vectorized Antibodies Major Product Offerings
7.7.4 Eli Lilly Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.7.5 Eli Lilly Key News & Latest Developments
7.8 Generation Bio
7.8.1 Generation Bio Company Summary
7.8.2 Generation Bio Business Overview
7.8.3 Generation Bio Vectorized Antibodies Major Product Offerings
7.8.4 Generation Bio Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.8.5 Generation Bio Key News & Latest Developments
7.9 Genmab
7.9.1 Genmab Company Summary
7.9.2 Genmab Business Overview
7.9.3 Genmab Vectorized Antibodies Major Product Offerings
7.9.4 Genmab Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.9.5 Genmab Key News & Latest Developments
7.10 GlaxoSmithKline
7.10.1 GlaxoSmithKline Company Summary
7.10.2 GlaxoSmithKline Business Overview
7.10.3 GlaxoSmithKline Vectorized Antibodies Major Product Offerings
7.10.4 GlaxoSmithKline Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.10.5 GlaxoSmithKline Key News & Latest Developments
7.11 Homology Medicines
7.11.1 Homology Medicines Company Summary
7.11.2 Homology Medicines Vectorized Antibodies Business Overview
7.11.3 Homology Medicines Vectorized Antibodies Major Product Offerings
7.11.4 Homology Medicines Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.11.5 Homology Medicines Key News & Latest Developments
7.12 Inovio Pharmaceuticals
7.12.1 Inovio Pharmaceuticals Company Summary
7.12.2 Inovio Pharmaceuticals Vectorized Antibodies Business Overview
7.12.3 Inovio Pharmaceuticals Vectorized Antibodies Major Product Offerings
7.12.4 Inovio Pharmaceuticals Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.12.5 Inovio Pharmaceuticals Key News & Latest Developments
7.13 Kernal Biologics
7.13.1 Kernal Biologics Company Summary
7.13.2 Kernal Biologics Vectorized Antibodies Business Overview
7.13.3 Kernal Biologics Vectorized Antibodies Major Product Offerings
7.13.4 Kernal Biologics Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.13.5 Kernal Biologics Key News & Latest Developments
7.14 VectorY
7.14.1 VectorY Company Summary
7.14.2 VectorY Business Overview
7.14.3 VectorY Vectorized Antibodies Major Product Offerings
7.14.4 VectorY Vectorized Antibodies Sales and Revenue in Global (2018-2023)
7.14.5 VectorY Key News & Latest Developments
8 Global Vectorized Antibodies Production Capacity, Analysis
8.1 Global Vectorized Antibodies Production Capacity, 2018-2029
8.2 Vectorized Antibodies Production Capacity of Key Manufacturers in Global Market
8.3 Global Vectorized Antibodies Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Vectorized Antibodies Supply Chain Analysis
10.1 Vectorized Antibodies Industry Value Chain
10.2 Vectorized Antibodies Upstream Market
10.3 Vectorized Antibodies Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Vectorized Antibodies Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Vectorized Antibodies in Global Market
Table 2. Top Vectorized Antibodies Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Vectorized Antibodies Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Vectorized Antibodies Revenue Share by Companies, 2018-2023
Table 5. Global Vectorized Antibodies Sales by Companies, (K Units), 2018-2023
Table 6. Global Vectorized Antibodies Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Vectorized Antibodies Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Vectorized Antibodies Product Type
Table 9. List of Global Tier 1 Vectorized Antibodies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Vectorized Antibodies Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Vectorized Antibodies Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Vectorized Antibodies Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Vectorized Antibodies Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Vectorized Antibodies Sales (K Units), 2018-2023
Table 15. By Type - Global Vectorized Antibodies Sales (K Units), 2024-2029
Table 16. By Application – Global Vectorized Antibodies Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Vectorized Antibodies Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Vectorized Antibodies Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Vectorized Antibodies Sales (K Units), 2018-2023
Table 20. By Application - Global Vectorized Antibodies Sales (K Units), 2024-2029
Table 21. By Region – Global Vectorized Antibodies Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Vectorized Antibodies Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Vectorized Antibodies Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Vectorized Antibodies Sales (K Units), 2018-2023
Table 25. By Region - Global Vectorized Antibodies Sales (K Units), 2024-2029
Table 26. By Country - North America Vectorized Antibodies Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Vectorized Antibodies Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Vectorized Antibodies Sales, (K Units), 2018-2023
Table 29. By Country - North America Vectorized Antibodies Sales, (K Units), 2024-2029
Table 30. By Country - Europe Vectorized Antibodies Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Vectorized Antibodies Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Vectorized Antibodies Sales, (K Units), 2018-2023
Table 33. By Country - Europe Vectorized Antibodies Sales, (K Units), 2024-2029
Table 34. By Region - Asia Vectorized Antibodies Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Vectorized Antibodies Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Vectorized Antibodies Sales, (K Units), 2018-2023
Table 37. By Region - Asia Vectorized Antibodies Sales, (K Units), 2024-2029
Table 38. By Country - South America Vectorized Antibodies Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Vectorized Antibodies Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Vectorized Antibodies Sales, (K Units), 2018-2023
Table 41. By Country - South America Vectorized Antibodies Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Vectorized Antibodies Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Vectorized Antibodies Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Vectorized Antibodies Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Vectorized Antibodies Sales, (K Units), 2024-2029
Table 46. 4D Molecular Therapeutics (4DMT) Company Summary
Table 47. 4D Molecular Therapeutics (4DMT) Vectorized Antibodies Product Offerings
Table 48. 4D Molecular Therapeutics (4DMT) Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. 4D Molecular Therapeutics (4DMT) Key News & Latest Developments
Table 50. AbbVie Company Summary
Table 51. AbbVie Vectorized Antibodies Product Offerings
Table 52. AbbVie Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. AbbVie Key News & Latest Developments
Table 54. Adverum Biotechnologies Company Summary
Table 55. Adverum Biotechnologies Vectorized Antibodies Product Offerings
Table 56. Adverum Biotechnologies Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Adverum Biotechnologies Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Vectorized Antibodies Product Offerings
Table 60. AstraZeneca Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. BioNTech Company Summary
Table 63. BioNTech Vectorized Antibodies Product Offerings
Table 64. BioNTech Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. BioNTech Key News & Latest Developments
Table 66. Curevac Company Summary
Table 67. Curevac Vectorized Antibodies Product Offerings
Table 68. Curevac Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Curevac Key News & Latest Developments
Table 70. Eli Lilly Company Summary
Table 71. Eli Lilly Vectorized Antibodies Product Offerings
Table 72. Eli Lilly Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Eli Lilly Key News & Latest Developments
Table 74. Generation Bio Company Summary
Table 75. Generation Bio Vectorized Antibodies Product Offerings
Table 76. Generation Bio Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Generation Bio Key News & Latest Developments
Table 78. Genmab Company Summary
Table 79. Genmab Vectorized Antibodies Product Offerings
Table 80. Genmab Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Genmab Key News & Latest Developments
Table 82. GlaxoSmithKline Company Summary
Table 83. GlaxoSmithKline Vectorized Antibodies Product Offerings
Table 84. GlaxoSmithKline Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. GlaxoSmithKline Key News & Latest Developments
Table 86. Homology Medicines Company Summary
Table 87. Homology Medicines Vectorized Antibodies Product Offerings
Table 88. Homology Medicines Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Homology Medicines Key News & Latest Developments
Table 90. Inovio Pharmaceuticals Company Summary
Table 91. Inovio Pharmaceuticals Vectorized Antibodies Product Offerings
Table 92. Inovio Pharmaceuticals Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Inovio Pharmaceuticals Key News & Latest Developments
Table 94. Kernal Biologics Company Summary
Table 95. Kernal Biologics Vectorized Antibodies Product Offerings
Table 96. Kernal Biologics Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Kernal Biologics Key News & Latest Developments
Table 98. VectorY Company Summary
Table 99. VectorY Vectorized Antibodies Product Offerings
Table 100. VectorY Vectorized Antibodies Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. VectorY Key News & Latest Developments
Table 102. Vectorized Antibodies Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 103. Global Vectorized Antibodies Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global Vectorized Antibodies Production by Region, 2018-2023 (K Units)
Table 105. Global Vectorized Antibodies Production by Region, 2024-2029 (K Units)
Table 106. Vectorized Antibodies Market Opportunities & Trends in Global Market
Table 107. Vectorized Antibodies Market Drivers in Global Market
Table 108. Vectorized Antibodies Market Restraints in Global Market
Table 109. Vectorized Antibodies Raw Materials
Table 110. Vectorized Antibodies Raw Materials Suppliers in Global Market
Table 111. Typical Vectorized Antibodies Downstream
Table 112. Vectorized Antibodies Downstream Clients in Global Market
Table 113. Vectorized Antibodies Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Vectorized Antibodies Segment by Type in 2022
Figure 2. Vectorized Antibodies Segment by Application in 2022
Figure 3. Global Vectorized Antibodies Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Vectorized Antibodies Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Vectorized Antibodies Revenue, 2018-2029 (US$, Mn)
Figure 7. Vectorized Antibodies Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Vectorized Antibodies Revenue in 2022
Figure 9. By Type - Global Vectorized Antibodies Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 11. By Type - Global Vectorized Antibodies Sales Market Share, 2018-2029
Figure 12. By Type - Global Vectorized Antibodies Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Vectorized Antibodies Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 15. By Application - Global Vectorized Antibodies Sales Market Share, 2018-2029
Figure 16. By Application - Global Vectorized Antibodies Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Vectorized Antibodies Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Vectorized Antibodies Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 20. By Region - Global Vectorized Antibodies Sales Market Share, 2018-2029
Figure 21. By Country - North America Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 22. By Country - North America Vectorized Antibodies Sales Market Share, 2018-2029
Figure 23. US Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Vectorized Antibodies Sales Market Share, 2018-2029
Figure 28. Germany Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 29. France Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Vectorized Antibodies Sales Market Share, 2018-2029
Figure 37. China Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 41. India Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 43. By Country - South America Vectorized Antibodies Sales Market Share, 2018-2029
Figure 44. Brazil Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Vectorized Antibodies Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Vectorized Antibodies Sales Market Share, 2018-2029
Figure 48. Turkey Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Vectorized Antibodies Revenue, (US$, Mn), 2018-2029
Figure 52. Global Vectorized Antibodies Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Vectorized Antibodies by Region, 2022 VS 2029
Figure 54. Vectorized Antibodies Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界のベクター化抗体市場予測2023-2029：アデノ随伴ウイルス（AAV）ベクター、エレクトロポレーション、脂質ナノ粒子（LNP）、その他] (コード：MMG23LY8199)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のベクター化抗体市場予測2023-2029：アデノ随伴ウイルス（AAV）ベクター、エレクトロポレーション、脂質ナノ粒子（LNP）、その他]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の獣医用ウイルスベクターワクチン市場予測2023-2029：アルファヘルペスウイルス（HVT）ベクター、カナリア痘ベクター、ワクシニアベクター
  • 世界の獣医用ウイルスベクター化ワクチン市場2022年：アルファヘルペスウイルス (HVT) ベクター、カナリア痘ベクター、ワクシニアベクター
  • 世界のグラフィックディスプレイ端末機市場2022年：ラスター、ベクター
  • 世界の一次抗体市場予測2023-2029：ポリクローナル、モノクローナル
  • 世界の細胞結合型二重特異性抗体市場予測2023-2029：T細胞エンゲージャー、NK細胞エンゲージャー

    • ◆H&Iグローバルリサーチのお客様（例）◆